Report: Impact of Biomedical Research Slipping

Despite dramatic increases in publications, the last 50 years have seen relatively little return on investment for US public health, a study suggests.

Written byJef Akst
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

FLICKR, UNDERSTANDING ANIMAL RESEARCHGiven relatively steady increases in funding (the last 10 years aside) and the number of new papers published each year, the US biomedical research community might expect to see greater outcomes over the past half century—in terms of the numbers of new drugs approved, for example, or gains in life expectancy. But, according to a study published yesterday (August 17) in PNAS, the amount of science being done has not directly translated into public-health benefits.

“The idea of public support for biomedical research is to make lives better. But there is increasing friction in the system,” coauthor Arturo Casadevall, a microbiologist at Albert Einstein College of Medicine in New York City, said in a press release. “We are spending more money now just to get the same results we always have, and this is going to keep happening if we don’t fix things.”

Casadevall teamed up with Anthony Bowen, an MD/PhD student at Johns Hopkins Bloomberg School of Public Health in Baltimore, to compare the “inputs” and “outputs” of biomedical science, such as annual National Institutes of Health budgets and publication numbers, with outcomes such as drug approvals and life expectancy since 1965. What they found didn’t quite add up. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies